Astrazeneca Plc $AZN Stock: Henry James International Management Inc. Reduces Stake

Henry James International Management Inc. trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 36.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,140 shares of the company’s stock after selling 13,512 shares during the period. Astrazeneca makes up approximately 1.1% of Henry James International Management Inc.’s portfolio, making the stock its 29th biggest holding. Henry James International Management Inc.’s holdings in Astrazeneca were worth $3,736,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Signal Advisors Wealth LLC raised its position in shares of Astrazeneca by 2.7% during the 3rd quarter. Signal Advisors Wealth LLC now owns 2,778 shares of the company’s stock valued at $448,000 after buying an additional 72 shares in the last quarter. B. Riley Wealth Advisors Inc. grew its position in Astrazeneca by 101.2% in the third quarter. B. Riley Wealth Advisors Inc. now owns 9,241 shares of the company’s stock worth $1,492,000 after acquiring an additional 4,647 shares in the last quarter. Forvis Mazars Wealth Advisors LLC grew its position in Astrazeneca by 5.4% in the third quarter. Forvis Mazars Wealth Advisors LLC now owns 2,321 shares of the company’s stock worth $375,000 after acquiring an additional 119 shares in the last quarter. Madson Wealth Advisors Inc increased its stake in Astrazeneca by 3.9% in the third quarter. Madson Wealth Advisors Inc now owns 3,344 shares of the company’s stock valued at $540,000 after acquiring an additional 126 shares during the last quarter. Finally, Sax Wealth Advisors LLC increased its stake in Astrazeneca by 37.6% in the third quarter. Sax Wealth Advisors LLC now owns 2,036 shares of the company’s stock valued at $329,000 after acquiring an additional 556 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citigroup restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, October 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Nordea Equity Research raised Astrazeneca from a “sell” rating to a “buy” rating in a report on Tuesday. Fifteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $206.67.

Astrazeneca Trading Up 4.2%

Shares of Astrazeneca stock traded up $6.58 during trading on Wednesday, reaching $162.40. The company’s stock had a trading volume of 1,452,581 shares, compared to its average volume of 2,793,238. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71. The firm’s 50-day moving average is $161.95 and its two-hundred day moving average is $176.56. The company has a market cap of $251.87 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 1.34 and a beta of 0.27.

Astrazeneca (NYSE:AZN) last issued its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.17 EPS. On average, sell-side analysts anticipate that Astrazeneca Plc will post 9.38 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.